Total revenue was $200.5 million, or $201.3 million on a non-GAAP constant currency basis, for the full year 2024, representing 3.9% and 3.9% increases, respectively, over the full year 2023 Expanded ...

“I am encouraged by the resilience of our portfolio amidst a challenging macroeconomic backdrop, exemplified by double-digit revenue growth in Cytek cell sorters and our service business, and strength ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...

Operator: Thank you for standing by. My name is Luella, and I will be your conference operator today. At this time, I would like to welcome everyone to Cytek Biosciences’ Second Quarter 2024 Earnings ...

In the preceding three months, 4 analysts have released ratings for Cytek Biosciences (NASDAQ:CTKB), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...

Cytek Biosciences, Inc. has announced that it will release its financial results for the first quarter of 2025 on May 8, 2025, after the market closes. Following the release, the company's management ...